The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.
Jean-Pascal H. Machiels
Consultant or Advisory Role - Boehringer Ingelheim
Lisa F. Licitra
No relevant relationships to disclose
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim (U)
Makoto Tahara
Consultant or Advisory Role - Merck Serono
Research Funding - Eisai; Yakult Honsha
Liz Svensson
Employment or Leadership Position - Boehringer Ingelheim
Xiuyu Julie Cong
Employment or Leadership Position - Boehringer Ingelheim
Eva Ehrnrooth
Employment or Leadership Position - Boehringer Ingelheim
Ezra E. W. Cohen
Consultant or Advisory Role - Boehringer Ingelheim (U)